Thanks, Bassil.
our that are protein will tools have in very interesting additional We using the cytokines likely clinic, two to internally Genentech. currently full advance at of coming so range our are the We the course follow. and into cytokines, native busy our several first have other year, one more in programs engineering one therapeutics. expect of turn two There been to cytokines partner,
potently, create short-acting and Now, but powerful native cytokines and these with evolved make rapidly, drugs, used have often when them immune locally responses by toxic. properties systemic to acting
toxicity has longer create for historically. duration Our keeps clinical use threshold their engineering limited under to therapeutic and that cytokine the remained activity
enhance tolerated, and its often First, hundredfold by more its acting receptors. reducing we small created in for Xtend sustained to better immune the persistence. has enhanced We in stimulating technology incorporate or preclinical changes cytokine Fc XmAb affinity further fusing multiple more by activity pharmacokinetics This cytokines slower to to stability designed models. our bispecific further them that the to in domains potency, far by lower
XmAbXXX XmAbXXX, program, is properties: avoids NK are a that for studies the combination undesirable that tumor and it T-reg we T-cell monotherapy therapies; and engineered unlike cancer escalation currently with broad is clinical our with Phase currently Genentech. and for in cancer activation for IL-XX for oncology We range one, of for course both potentially is dose solid the IL-X, two, partnered bias assessing first X therapy. Our in is for IL-XX engineer therapy which combination these advanced other cell is in of additional patients, atezolizumab future. in activation, intrinsic cancer
receptor Genentech. Our is currently partner, first immune our in IL-XX with IND-enabling studies targeted
fusion second for treatment activate the selectively IL-X the Our our to in XmAbXXX, Fc disease. cytokine T-cells T-regs clinic or wholly-owned autoimmune of regulatory is engineered
the the study the and including a single-ascending effector key conducting pro-inflammatory long study therapy systemic X are measures provide pharmacokinetics volunteers of dose of include avoiding of IL-X for biomarkers, of of T-reg analysis an autoimmune expansion. Phase and tolerability of to goal activation healthy characterize The an safety, while to We intensity T-regs, will T-cells. XmAbXXX in activation delivered is disease sustained subcutaneously
maybe across diseases the could many therapeutic with a window compared and to studies indicate for preclinical IL-X this broad therapy So, historic have XmAbXXX. expanded autoimmune different potential T-reg-selective case IL-X approaches an
and to duration As used XmAb life. our its technology its of action we with Fc half cytokines, and reduced engineered potency domain to tolerability extend and enhance other our improve heterodimeric
newest program Our program. is preclinical cytokine a IL-XX
Our XmAbXXX. builds our prior work with IL-XX and cytokine XmAbXXX on program
of secretion both Now, visible significant immunogenicity IL-XX NK those and of can the proliferation antigens cell promotes increasing and increase tumor T-cells pro-inflammatory to gamma making cells a is thereby and that It our tumor potent immune of high for the promote cytokine the levels also cytotoxicity microenvironment types. can system. more
therapeutic was prior talk window, a and about demonstrated its will with I in that studies as seen cytokines anti-tumor have clinical but activity, IL-XX Now, narrow utility. strong limiting other to
methods to engineering to in again more acting for tolerable IL-XX an and lead the potency-reduced, we and IND we our generate So, cytokine submitting drug anticipate applied longer candidates XXXX.
engage designed other is activation bispecific in CDXX to mechanisms the tumor-selective like review a Now, checkpoint therapies. targeting T-cell-directed inhibition receptor using activity tumor a of we which by difficult by to as a domain CDXX immune to platform, key of way moment been a antibody, to a to that therapeutically. I engager T-cells engagement. on complement CDX has of and or enhance safely our a to take T-cell effectively new path But co-stimulatory is class would such a can T-cell CDXX-binding T-cells targeted boost
a candidate Our expressed. to most is for an through BX-HX where lead molecule broad file XmAbXXX, plan in CDXX preclinical we is development and antibody That solid advancing in CDXX potentially highly x tumor prostate including cancer bispecific wholly-owned advanced BX-HX is XXXX. use, IND
The with have we tumor a target. program collaboration and of well prostate focus second Janssen, a against where research the underway antibody bispecific CDXX CDXX partnered our discovered is
PD-LX target as in platform. another remain Finally, for interested this we
show candidates clinical supply the While pipeline programs molecules. create could that power differentiated that Xencor’s with platform biologies of access these new continually our to
to that, Now over will John hand key John? review financials. our highlights I Officer, quarter Kuch, second call with Chief Financial our the will from who
